Last Updated2026-06-02

Market View

₹34.37(▼1.29%)

Reporting PeriodQ4 FY26

BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited Forensic Risk Analysis

Name: Biofil Chemicals & Pharmaceuticals Limited Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market Cap₹49 Cr

Primary DriverGrowth Sustainability

Flagium AI Risk Score

19 / 100

+4 QoQ

Early Deterioration

Sentinel Insight

Financial profile remains stable for now. Weakness is detected in growth sustainability. No immediate concerns are visible. Risk is gradually increasing.

50.5th %ile (Sector)Accel: +1 Qtrs

Updated2026-06-02

Market View

₹34.37▼1.29%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Growth Sustainability

+10.0 pts

Balance Sheet Stress

+8.8 pts

Final Composite Risk19 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 5 → 19 over 13 quarters.

Expected Direction

⚠ Watch

Primary Deterioration Drivers

Inventory Stress
Industrial Margin Stress
Working Capital Expansion

What to Watch Next Quarter

Inventory turnover
Operating profit margins
Operating cash flow

Active Risk Objects (6)

CriticalHigh

Inventory Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight15/15

MomentumAccelerating

Last SignalQ4 FY2026

Inventory growth (19.7%) significantly outpaced revenue growth (-10.6%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Profit Collapse

📊 Earnings QualityQuarterlyActive for 2 Qtrs

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ3 FY2026

BIOFILCHEM: Net Profit collapsed by 51.9% from FY2025 Q3 to FY2026 Q3.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Industrial Margin Stress

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight12/15

MomentumPersistent

Last SignalQ3 FY2026

BIOFILCHEM: Raw material costs consumed an additional 321.6% of revenue YoY.

"Margins are in freefall. Operating costs are growing significantly faster than revenue."

Cash Conversion Deficit

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight6/15

MomentumPersistent

Last SignalFY2026

BIOFILCHEM: OCF below Net Profit in 2/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Working Capital Expansion

💧 Liquidity & CoverageAnnualActive for 4 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ4 FY2026

Working capital expansion detected: Receivable days increased by -19.4%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Revenue-Debt Divergence

🏛️ Solvency & LeverageAnnualActive for 2 Years

More Detail

Impact Weight6/15

MomentumAccelerating

Last SignalFY2026

BIOFILCHEM: Revenue fell 6.6% while Debt rose 540.8% in 2026 vs 2025.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	6.17	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+47.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹34.37(-1.29%)

1M Divergence-1.33%

1 Week-6.91%

1 Month+0.94%

6 Months+1.15%

1 Year-29.15%

2 Year-45.05%

3 Year-21.53%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in growth sustainability remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

BIOFILCHEM • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.12%

Trend QualityStabilizing

Phase Progression

Phase Progression Score55%

Readiness LabelModerate (Transition Potential Building)

Probability of Advancing12%

CoinTree Momentum

Composite Z-Score+0.2757σ

Improving momentum strength

Universe Rank#629 of 2716

Top 23.16% in momentum strength

Timeframe Sparklines

1W-6.9%

1M+0.9%

6M+1.1%

Weinstein Indicators

150 DMA₹34.07

200 DMA₹36.19

150 DMA Slope-2.9636%Declining

Relative Strength+7.77%Leading

Relative Turnover (RTR)1.5069

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited	19	51th	+4	6	+1	Growth SustainabilityStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch
AARTIPHARMAarti Pharmalabs Limited	35	81th	0	18	+0	Earnings QualityWatch
ALBERTDAVDAlbert David Limited	37	90th	-8	27	+0	Balance Sheet StressWatch